Abstract:Objective: Cholesterol gallstone disease (CGD) is closely related to cholesterol metabolic disorder. Glutaredoxin-1 (Glrx1) and Glrx1-related protein S-glutathionylation are increasingly being observed to drive various physiological and pathological processes, especially in metabolic diseases such as diabetes, obesity and fatty liver. However, Glrx1 has been minimally explored in cholesterol metabolism and gallstone disease.Methods: We first investigated whether Glrx1 plays a role in gallstone formation in lithogenic diet-fed mice using immunoblotting and quantitative real-time PCR. Then a whole-body Glrx1-deficient (Glrx1-/- ) mice and hepaticspecific Glrx1-overexpressing (AAV8-TBG-Glrx1) mice were generated, in which we analyzed the effects of Glrx1 on lipid metabolism upon LGD feeding. Quantitative proteomic analysis and immunoprecipitation (IP) of glutathionylated proteins were performed.Results: We found that protein S-glutathionylation was markedly decreased and the deglutathionylating enzyme Glrx1 was greatly increased in the liver of lithogenic diet-fed mice. Glrx1-/- mice were protected from gallstone disease induced by a lithogenic diet because their biliary cholesterol and cholesterol saturation index (CSI) were reduced. Conversely, AAV8-TBG-Glrx1 mice showed greater gallstone progression with increased cholesterol secretion and CSI. Further studies showed that Glrx1-overexpressing greatly altered bile acid levels and/or composition to increase intestinal cholesterol absorption by upregulating Cyp8b1. In addition, liquid chromatography-mass spectrometry and IP analysis revealed that Glrx1 also affected the function of asialoglycoprotein receptor 1 (ASGR1) by mediating its deglutathionylation, thereby altering the expression of LXR & alpha; and controlling cholesterol secretion. Conclusion: Our findings present novel roles of Glrx1 and Glrx1-regulated protein S-glutathionylation in gallstone formation through the targeting of cholesterol metabolism. Our data advises Glrx1 significantly increased gallstone formation by simultaneously increase bile-acid-dependent cholesterol absorption and ASGR1- LXR & alpha;dependent cholesterol efflux. Our work suggests the potential effects of inhibiting Glrx1 activity to treat cholelithiasis.

Glutaredoxin 1 Regulates Cholesterol Metabolism and Gallstone Formation by Influencing Protein S-glutathionylation

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Regulatation of Hepatic Lipid Metabolism by Glutaredoxin‐1 and Protein Glutathione‐adducts

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

Adeno-associated Virus-Based Caveolin-1 Delivery Via Different Routes for the Prevention of Cholesterol Gallstone Formation

PXR Prevents Cholesterol Gallstone Disease by Regulating Biosynthesis and Transport of Bile Salts.

Pxr Prevents Cholesterol Gallstone Disease by Affecting Bile Acid Biosynthesis and Transport

Activation Of Liver X Receptor Sensitizes Mice To Gallbladder Cholesterol Crystallization

Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.

Peroxisome Proliferator-Activated Receptor-γ Prevents Cholesterol Gallstone Formation in C57bl Mice by Regulating Bile Acid Synthesis and Enterohepatic Circulation

Characteristics of Mrna Levels of Hepatic Cholesterol Metabolism Regulatory Enzymes in Genetically Gallstone-Susceptible and Resistant Mice

Activation of Constitutive Androstane Receptor Prevents Cholesterol Gallstone Formation

Glutaredoxin-1 Alleviates Acetaminophen-Induced Liver Injury by Decreasing Its Toxic Metabolites

Association of Caveolin-3 and Cholecystokinin A Receptor with Cholesterol Gallstone Disease in Mice

FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strains

Glutaredoxin1 Knockout Promotes High-Fat Diet-Induced Obesity in Male Mice but Not in Female Ones.

Dietary diosgenin transcriptionally down-regulated intestinal NPC1L1 expression to prevent cholesterol gallstone formation in mice

CAV1 Prevents Gallbladder Cholesterol Crystallization by Regulating Biosynthesis and Transport of Bile Salts

Ganoderma lucidum polysaccharide ameliorates cholesterol gallstone formation by modulating cholesterol and bile acid metabolism in an FXR-dependent manner

Increased expression of LXRα, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients Published, JLR Papers in Press, November 15, 2007.

FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice